No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Good Position To Deliver On Growth Plans
Cantor Fitzgerald Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating
MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $81
Guggenheim Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $80
RBC Capital Initiates MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Announces Target Price $67
